Comparing Opzelura vs Zoryve
| Opzelura (ruxolitinib) | Zoryve (roflumilast) |
|
|---|
| Opzelura (ruxolitinib) | Zoryve (roflumilast) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Vitiligo, Atopic Dermatitis. Opzelura may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Plaque Psoriasis. Zoryve may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Opzelura (ruxolitinib) | More about Zoryve (roflumilast) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Opzelura has an average rating of 9.3 out of 10 from a total of 6 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Zoryve has an average rating of 8.7 out of 10 from a total of 51 ratings on Drugs.com. 80% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Opzelura side effects |
View all Zoryve side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Opzelura prices |
View all Zoryve prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
Other roflumilast brands include: Zoryve Foam | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
116 hours |
9.6 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 336 drugs are known to interact with Opzelura:
|
A total of 103 drugs are known to interact with Zoryve:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | |||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| First Approval Date | |||||||||||||||||
|
September 21, 2021 |
July 29, 2022 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Eucrisa
Eucrisa (crisaborole) is used to treat mild to moderate eczema (atopic dermatitis) Includes Eucrisa ...
Adbry
Adbry is used to treat moderate-to-severe atopic dermatitis (eczema) in adults and children aged 12 ...
Cibinqo
Cibinqo (abrocitinib) tablets are used for the treatment of moderate to severe eczema (atopic ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.